Title |
Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy
|
---|---|
Published in |
Journal of Translational Medicine, December 2011
|
DOI | 10.1186/1479-5876-9-209 |
Pubmed ID | |
Authors |
Phuc V Pham, Nhan LC Phan, Nhung T Nguyen, Nhung H Truong, Thuy T Duong, Dong V Le, Kiet D Truong, Ngoc K Phan |
Abstract |
Breast cancer stem cells (BCSCs) are the source of breast tumors. Compared with other cancer cells, cancer stem cells show high resistance to both chemotherapy and radiotherapy. Targeting of BCSCs is thus a potentially promising and effective strategy for breast cancer treatment. Differentiation therapy represents one type of cancer stem-cell-targeting therapy, aimed at attacking the stemness of cancer stem cells, thus reducing their chemo- and radioresistance. In a previous study, we showed that down-regulation of CD44 sensitized BCSCs to the anti-tumor agent doxorubicin. This study aimed to determine if CD44 knockdown caused BCSCs to differentiate into breast cancer non-stem cells (non-BCSCs). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | <1% |
Italy | 1 | <1% |
India | 1 | <1% |
United Kingdom | 1 | <1% |
China | 1 | <1% |
Japan | 1 | <1% |
Unknown | 139 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 39 | 27% |
Researcher | 26 | 18% |
Student > Bachelor | 18 | 12% |
Student > Master | 15 | 10% |
Student > Doctoral Student | 12 | 8% |
Other | 15 | 10% |
Unknown | 20 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 40 | 28% |
Biochemistry, Genetics and Molecular Biology | 38 | 26% |
Medicine and Dentistry | 23 | 16% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
Engineering | 4 | 3% |
Other | 9 | 6% |
Unknown | 25 | 17% |